State Street SPDR S&P Biotech ETF (NY:XBI)
159.69
+2.28
(+1.45%)
Streaming Delayed Price
Updated: 1:09 PM EDT, Aug 17, 2026
Add to My Watchlist
Price and Volume
Detailed Quote| Volume | 3,011,147 |
| Open | 156.83 |
| Bid (Size) | 159.68 (100) |
| Ask (Size) | 159.72 (200) |
| Prev. Close | 157.41 |
| Today's Range | 155.86 - 159.77 |
| 52wk Range | 88.18 - 165.71 |
| Shares Outstanding | 541,500 |
| Dividend Yield | 0.17% |
Top News
More News
Performance
More News
Read More
The Best Biotech Stocks to Buy in 2026 ↗
June 17, 2026
3 Longevity ETFs to Buy and Hold (and Hold) ↗
June 08, 2026
2 Ways to Play the Big Pharma Patent Cliff ↗
May 15, 2026
Why Did CRMD Stock Tumble Over 11% Today? ↗
March 05, 2026
Why Did BTAI Stock Surge 20% In Pre-Market Today? ↗
March 05, 2026
Frequently Asked Questions
Is State Street SPDR S&P Biotech ETF publicly traded?
Yes, State Street SPDR S&P Biotech ETF is publicly traded.
What exchange does State Street SPDR S&P Biotech ETF trade on?
State Street SPDR S&P Biotech ETF trades on the New York Stock Exchange
What is the ticker symbol for State Street SPDR S&P Biotech ETF?
The ticker symbol for State Street SPDR S&P Biotech ETF is XBI on the New York Stock Exchange
What is the current price of State Street SPDR S&P Biotech ETF?
The current price of State Street SPDR S&P Biotech ETF is 159.69
When was State Street SPDR S&P Biotech ETF last traded?
The last trade of State Street SPDR S&P Biotech ETF was at 08/17/26 01:09 PM ET
What is the market capitalization of State Street SPDR S&P Biotech ETF?
The market capitalization of State Street SPDR S&P Biotech ETF is 86.47M
How many shares of State Street SPDR S&P Biotech ETF are outstanding?
State Street SPDR S&P Biotech ETF has 86M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.